Drug Trial Radar · NCT06361186
Proximod Pharmacokinetics In Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
134
Actual
Start
Sep 14, 2017
Primary completion
Nov 1, 2017
Study completion Jun 22, 2021
Sponsor
- Lead sponsor
- Longevity Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the tolerability, pharmacokinetics and pharmacodynamics of Proximod in healthy subjects. The main questions it arms to answer are: 1. to evaluate the safety and tolerance of Proximod in healthy subjects after single or repeated doses. 2. to learn the pharmacodynamics of Proximod in healthy subjects after single or repeated doses. 3. to evaluation of the effect of food on the pharmacokinetics of Proximod in healthy subjects Participants will receive test tablets or placebo at the indicated date and collect blood samples.
Conditions
- Rheumatoid Arthritis
Interventions
ProximodDrug
Single and multiple-dose to establish the safety and PK profile
PlaceboDrug
Placebo controlled
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak plasma concentration (Cmax)Time frame: Up to 64 days
- Time to peak plasma concentration (Tmax)Time frame: Up to 64 days
- The lowest plasma concentration (Cmin)Time frame: Up to 64 days
- Half-life (t1/2)Time frame: Up to 64 days
- Number of adverse events and number of participants with adverse eventsTime frame: Up to 64 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The first hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.